DGAP-News

amp biosimilars AG successfully out-licenses first biosimilar

DGAP-News: amp biosimilars AG / Key word(s): Agreement/Miscellaneous
amp biosimilars AG successfully out-licenses first biosimilar

28.05.2015 / 08:00

---------------------------------------------------------------------

amp biosimilars AG successfully out-licenses first biosimilar

- First out-licensing of an oncology biosimilar from the ampb product
pipeline

- Partner to finance development and market authorization

- Partner to receive rights for China; rights for the rest of the world
remain with ampb

Hamburg, Germany, May 28, 2015 - amp biosimilars AG (ISIN: DE000A0SMU87), a
company specializing in the development of high-quality biosimilars, today
announced its first successful out-licensing of a biosimilar. The first
biosimilar to be out-licensed from the product pipeline is ABY-018, a
humanized monoclonal antibody. At present, there are four biosimilars in
the ampb product pipeline.

amp biosimilars licensed the biosimilar to a leading mid-sized Chinese
pharmaceutical corporation, with a portfolio of more than 50 pharmaceutical
products, a GMP-certified production capacity of two billion tablets and
one billion capsules per year as well as a national sales network that puts
it in an excellent position to pursue commercialization in China.

The partner will assume all financing for the development and market
approval processes starting from Clinical Phase I through to production and
marketing of the biosimilar in China. The partner will have the right to
unlimited marketing in China and shall pay a percentage of the proceeds to
amp biosimilars (royalties). amp biosimilars retains the global rights
outside of China. This arrangement allows amp biosimilars to conclude
additional out-licensing agreements for the biosimilar, for example in the
US, Europe and other Asian countries, or to develop the relevant markets
independently and thus generate greater potential revenues. By way of
reciprocation, ampb will pay the Chinese partner royalties in the same
amount.

"Our team is very happy with this outcome. We have just cleared a decisive
hurdle, validating the strength of our business model," says Dr. Marc W.
Hentz, Chief Executive Officer of amp biosimilars AG. "By out-licensing to
China, we are not only tapping into the potential represented by this
rapidly expanding market, but also have the opportunity of forming
partnerships with companies in other markets outside of China. This